[Rapport de recherche] Le marché de la neuropathie périphérique induite par la chimiothérapie devrait atteindre 1 174,26 millions USD d'ici 2028, contre 813,48 millions USD en 2021 ; il devrait enregistrer un TCAC de 5,4 % de 2021 à 2028.
La neuropathie périphérique induite par la chimiothérapie est l'un des effets secondaires les plus fréquents causés par les agents antinéoplasiques . Sur le plan clinique, il s'agit d'une neuropathie essentiellement sensorielle qui peut s'accompagner de modifications motrices et autonomes d'intensité et de durée variables. En raison de sa prévalence élevée chez les patients cancéreux, la neuropathie périphérique induite par la chimiothérapie constitue un problème majeur pour les patients cancéreux et les survivants ainsi que pour leurs prestataires de soins de santé, en particulier parce qu'il n'existe actuellement aucune méthode efficace pour la prévenir ; de plus, les possibilités de traitement de ce syndrome sont limitées.
Personnalisez ce rapport en fonction de vos besoins
Vous bénéficierez d'une personnalisation gratuite de n'importe quel rapport, y compris de certaines parties de ce rapport, d'une analyse au niveau des pays, d'un pack de données Excel, ainsi que d'offres et de remises exceptionnelles pour les start-ups et les universités.
Marché de la neuropathie périphérique induite par la chimiothérapie : informations stratégiques
- Obtenez les principales tendances clés du marché de ce rapport.Cet échantillon GRATUIT comprendra une analyse de données, allant des tendances du marché aux estimations et prévisions.
Le rapport offre des informations et une analyse approfondie du marché de la neuropathie périphérique induite par la chimiothérapie (CIPN) en mettant l’accent sur les tendances du marché, les avancées technologiques et la dynamique du marché. Il fournit également l’analyse du paysage concurrentiel des principaux acteurs du marché à travers le monde. En outre, le rapport inclut l’impact de la pandémie de COVID-19 sur le marché de la neuropathie périphérique induite par la chimiothérapie dans toutes les régions. La pandémie a créé à la fois une crise de santé publique et une crise économique dans le monde entier. Le marché mondial de la neuropathie périphérique induite par la chimiothérapie avant la pandémie était en constante croissance en raison de la régularité du dépistage du cancer, des consultations et des traitements. La première vague de COVID-19 a perturbé les consultations, les suivis et les dépistages des cas oncologiques. De plus, les perturbations des essais cliniques et de l’approvisionnement en médicaments des patients au début de la pandémie de COVID-19 ont eu un impact sur les domaines les plus cruciaux du marché de la neuropathie périphérique induite par la chimiothérapie . Un changement d’orientation vers le traitement rapide du COVID-19 a conduit à une négligence envers diverses autres conditions médicales. De plus, la diminution du nombre de cas de cancer détectés et des séances de chimiothérapie à des fins de traitement a entravé la demande de diagnostics et de traitements de neuropathie périphérique induite par chimiothérapie . CIPN) market emphasizing market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players across the world. Furthermore, the report includes the impact of the COVID-19 pandemic on the oncological cases. Moreover, disruptions in clinical trials and drug supply to patients during the early stage of the COVID-19 pandemic impacted the most crucial areas of the chemotherapy induced peripheral
Informations sur le marché
La prévalence croissante du cancer stimule la croissance du marché de la neuropathie périphérique induite par la chimiothérapie
Le cancer est l’une des principales causes de décès dans le monde. Selon l’Organisation mondiale de la santé (OMS), le cancer était la première cause de décès chez les personnes de moins de 70 ans dans 183 pays et la quatrième cause de décès parmi la population de tous âges dans 123 pays en 2019. En outre, selon les données publiées par l’OMS en mars 2021, différents types de cancer ont causé environ 10 millions de décès en 2020.
Formes de cancer les plus répandues dans le monde, 2020
- Cet échantillon GRATUIT comprendra une analyse de données, allant des tendances du marché aux estimations et prévisions.
La prévalence croissante du cancer a créé un fardeau pour les systèmes de santé du monde entier, tout en augmentant la demande de chimiothérapie. La neuropathie périphérique induite par la chimiothérapie est un effet indésirable courant des médicaments anticancéreux neurotoxiques, tels que les médicaments dérivés du platine (cisplatine et oxaliplatine), les poisons du fuseau [taxanes (paclitaxel et docétaxel), alcaloïdes de la pervenche, vincristine, épothilones et éribuline], le bortézomib et la thalidomide. La prévalence élevée de la neuropathie périphérique induite par la chimiothérapie suscite des inquiétudes chez les patients atteints de cancer et les survivants, ainsi que chez leurs prestataires de soins de santé, notamment parce qu'il n'existe pas de moyen unique et efficace de prévenir cette affection.neuropathy is a common adverse effect of neurotoxic anticancer drugs, such as platinum-derivative drugs (cisplatin and oxaliplatin), spindle poisons [taxanes (paclitaxel and docetaxel), vinca alkaloids, vincristine, epothilones, and eribulin], bortezomib, and thalidomide. The high prevalence of chemotherapy-induced peripheral neuropathy raises concerns about cancer patients and survivors, and their healthcare providers, especially because there is no single effective way to prevent this condition.
Français Dans une étude menée par « The Journal of the International Association for the Study of Pain », la prévalence de la neuropathie périphérique induite par la chimiothérapie a été rapportée à 68,1 % (57,7-78,4) lorsqu'elle est mesurée au cours du premier mois après la chimiothérapie, 60,0 % (36,4-81,6) au cours du troisième mois et 30,0 % (6,4-53,5) au cours du sixième mois ou plus. Ainsi, l'incidence croissante de la neuropathie périphérique induite par la chimiothérapie avec la prévalence croissante du cancer stimule la croissance du marché de la neuropathie périphérique induite par la chimiothérapie.neuropathy prevalence was reported at 68.1% (57.7–78.4 when measured in the first month after chemotherapy, 60.0% (36.4–81.6) in the third month, and 30.0% (6.4–53.5) in the sixth month or later. Thus, the growing incidence of chemotherapy-induced peripheral neuropathy with the increasing prevalence of cancer boosts the growth of the chemotherapy-induced peripheral neuropathy market.
Informations basées sur les classes de médicaments
En fonction de la classe de médicaments, le marché de la neuropathie périphérique induite par la chimiothérapie est segmenté en stéroïdes, antidépresseurs, antiépileptiques et narcotiques. En 2021, le segment des stéroïdes détenait la plus grande part du marché. Le segment des antiépileptiques devrait enregistrer le TCAC le plus rapide de 6,2 % au cours de la période de prévision. neuropathy market is segmented into steroids, antidepressants, anti-seizure, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure segment is expected to register the fastest CAGR of 6.2% during the forecast period.
Informations basées sur les canaux de distribution
En fonction du canal de distribution, le marché de la neuropathie périphérique induite par la chimiothérapie est segmenté en pharmacie hospitalière, pharmacie de détail et pharmacie en ligne. En 2021, le segment des pharmacies hospitalières détenait la plus grande part du marché. En outre, le segment des pharmacies de détail devrait enregistrer le TCAC le plus élevé de 5,9 % au cours de la période 2021-2028.neuropathy market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2021, the hospital pharmacy segment held the largest share of the market. Further, the retail pharmacy segment is expected to report the highest CAGR of 5.9% during 2021–2028.
Les acteurs du marché de la neuropathie périphérique induite par la chimiothérapie (CIPN) se concentrent sur l'adoption de stratégies organiques telles que le lancement et l'expansion de produits pour étendre leur empreinte et leur portefeuille de produits dans le monde entier, ainsi que pour répondre aux demandes croissantes.neuropathy (CIPN) market players focus on adopting organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide, as well as to meet the growing demands.
Portée du rapport sur le marché de la neuropathie périphérique induite par la chimiothérapieNeuropathy Market Report Scope
Par géographie
Sur la base de la géographie, le marché de la neuropathie périphérique induite par la chimiothérapie est segmenté en Amérique du Nord (États-Unis, Canada et Mexique), Europe (Royaume-Uni, Allemagne, France, Italie, Espagne et reste de l'Europe), Asie-Pacifique (Chine, Japon, Inde, Australie, Corée du Sud et reste de l'Asie-Pacifique), Moyen-Orient et Afrique (EAU, Arabie saoudite, Afrique du Sud et reste du Moyen-Orient et de l'Afrique) et Amérique du Sud et centrale (Brésil, Argentine et reste de l'Amérique du Sud et centrale).neuropathy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Profils d'entreprise
- Regency Pharmaceuticals, Inc.
- Asahi Kasei Pharma Corporation
- Novaremed
- Makscientific, SARL
- Wex Pharmaceutiques Inc.
- Sova Pharmaceuticals, Inc.
- Kineta, Inc.
- Aptinyx Inc.
- Apexian Pharmaceuticals, Inc.
- Winsantor, Inc.
Portée du rapport sur la neuropathie périphérique induite par la chimiothérapieNeuropathy Report Scope
| Attribut de rapport | Détails |
|---|---|
| Taille du marché en 2021 | 813,48 millions de dollars américains |
| Taille du marché d'ici 2028 | 1 174,26 millions de dollars américains |
| Taux de croissance annuel moyen mondial (2021-2028)CAGR (2021 - 2028) | 5,4% |
| Données historiques | 2019-2020 |
| Période de prévision | 2022-2028 |
| Segments couverts | Par classe de médicaments
|
| Régions et pays couverts | Amérique du Nord
|
| Leaders du marché et profils d'entreprises clés |
|
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The chemotherapy induced peripheral neuropathy market majorly consists of the players such as Regenacy Pharmaceuticals, Inc, Asahi Kasei Pharma Corporation., Novaremed, Makscientific, Llc, Wex Pharmaceuticals Inc., Sova Pharmaceuticals, Inc., Kineta, Inc., Aptinyx Inc., Apexian Pharmaceuticals, Inc., and Winsantor, Inc. amongst others.
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited.
The chemotherapy induced peripheral neuropathy market, by drug class, is bifurcated into steroids, antidepressants, anti-seizure medicines, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure medicines segment of the chemotherapy induced peripheral neuropathy market is expected to witness growth in its demand at the fastest CAGR during the forecast period.
The factors that are driving and restraining factors that will affect the chemotherapy induced peripheral neuropathy market in the coming years. Major factors driving the market growth include the increasing prevalence of cancer and increasing preference for chemotherapy. Additionally, the growing clinical trials for chemotherapeutic drugs is likely to emerge as a significant future trend in the market during the forecast period. However, lack of consolidated guidelines for chemotherapy hamper the chemotherapy induced peripheral neuropathy market growth.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Chemotherapy Induced Peripheral Neuropathy Market
- REGENACY PHARMACEUTICALS, INC
- ASAHI KASEI PHARMA CORPORATION
- NOVAREMED
- MAKSCIENTIFIC, LLC
- WEX PHARMACEUTICALS INC
- SOVA PHARMACEUTICALS, INC
- KINETA, INC.
- APTINYX INC.
- APEXIAN PHARMACEUTICALS, INC.
- WINSANTOR, INC
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For